Keyword: Kymriah (tisagenlecleucel)
A new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price of $475,000.
After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.
Intent to focus on the first -ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
Novartis brought on Pfizer executive—and Ibrance launch leader—Liz Barrett to head up its oncology outfit after Bruno Strigini's retirement.
There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.
Spark's pioneering Luxturna won FDA approval Tuesday to become the first gene therapy to target disease caused by a specific mutation.
Some critics point to the $373,000 price for Gilead's Yescarta as the problem holding up reimbursement, but it may be more nuanced than that.
Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.